Pgiam/iStock by way of Getty Photographs
Nkarta (NASDAQ:NKTX) shares spiked within the premarket Wednesday after Raymond James upgraded the cell remedy developer to Robust Purchase from Outperform, citing a compelling valuation setup following the corporate’s quarterly outcomes.
With its Q2 2024 financials on Tuesday, the California-based biotech indicated a money runway into late 2027, which, in keeping with Ray Jay analyst Laura Prendergast, will assist the corporate navigate “quite a few de-risking catalysts.”
Moreover, the analyst identified that Nkarta (NKTX) is buying and selling beneath money, and buyers have but to understand its lead product candidate, NKX019, an NK cell remedy in medical trials for autoimmune situations.
Prendergast identified that NK cell remedy has a number of benefits in comparison with T cell remedy, together with these associated to security and administration. These options may give NKTX an “edge for maneuvering the enrollment headwinds the house is dealing with,” the analyst wrote, conserving her $16 goal on the inventory unchanged.
